Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical Trial
Conditions: HER2-positive Metastatic Breast Cancer; First-line Treatment Interventions: Drug: disitamab vedotin; Drug: Pyrotinib; Drug: trastuzumab; Drug: Pertuzumab; Drug: taxane drug Sponsors: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Breast Cancer | Cancer | Cancer & Oncology | Clinical Trials | HER2 | Herceptin | Hospitals | Research